Published in Immunol Cell Biol on June 06, 2016
Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis. EBioMedicine (2017) 0.78
Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol (2005) 24.22
Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature (2011) 13.23
B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med (2008) 12.90
A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med (2006) 11.29
Epstein-Barr virus: 40 years on. Nat Rev Cancer (2004) 9.70
CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity (2010) 5.13
Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol (2001) 5.08
Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol (2007) 5.01
Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet (2013) 4.62
Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol (2010) 4.21
Cracking the BAFF code. Nat Rev Immunol (2009) 3.95
Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis (2003) 3.73
Regulation of the T-independent humoral response by TACI. Immunity (2001) 3.43
Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity (1998) 3.10
Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med (2007) 2.88
Atacicept in multiple sclerosis (ATAMS): a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Neurol (2014) 2.35
Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol (2006) 2.06
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol (2005) 2.02
Abnormal B-cell cytokine responses a trigger of T-cell-mediated disease in MS? Ann Neurol (2010) 1.97
Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology (2009) 1.93
Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol (2004) 1.89
TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood (2007) 1.85
Detection and quantification of latently infected B lymphocytes in Epstein-Barr virus-seropositive, healthy individuals by polymerase chain reaction. J Clin Microbiol (1992) 1.66
Novel function of B cell-activating factor in the induction of IL-10-producing regulatory B cells. J Immunol (2010) 1.57
Regulation of CXCR3 and CXCR4 expression during terminal differentiation of memory B cells into plasma cells. Blood (2005) 1.51
B cells in multiple sclerosis: connecting the dots. Curr Opin Immunol (2011) 1.45
Regulatory B cells in autoimmunity: developments and controversies. Nat Rev Rheumatol (2010) 1.34
Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain (2008) 1.33
Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain (2008) 1.24
Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands. Cell (2002) 1.23
Epstein-Barr virus latent infection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J Neuropathol Exp Neurol (2010) 1.15
Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein. Eur J Immunol (2010) 1.13
Treatment of multiple sclerosis with anti-CD20 antibodies. Clin Immunol (2011) 1.10
Atacicept: targeting B cells in multiple sclerosis. Ther Adv Neurol Disord (2010) 1.08
Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma. Cancer Res (2012) 1.08
Abnormal B cell differentiation in primary Sjögren's syndrome results in a depressed percentage of circulating memory B cells and elevated levels of soluble CD27 that correlate with Serum IgG concentration. Clin Immunol (2002) 1.06
Intrinsic properties of human and murine memory B cells. Immunol Rev (2006) 1.05
Interferon-beta-1b-induced short- and long-term signatures of treatment activity in multiple sclerosis. Pharmacogenomics J (2012) 1.04
Autoimmune disease: A role for new anti-viral therapies? Autoimmun Rev (2011) 1.03
Formation of virus-like clusters is an intrinsic property of the tumor necrosis factor family member BAFF (B cell activating factor). Biochemistry (2006) 0.99
A pharmacogenetic study implicates SLC9a9 in multiple sclerosis disease activity. Ann Neurol (2015) 0.97
Increased CD8+ T cell response to Epstein-Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog (2013) 0.92
The TACI receptor regulates T-cell-independent marginal zone B cell responses through innate activation-induced cell death. Immunity (2013) 0.88
IFN-β treatment requires B cells for efficacy in neuroautoimmunity. J Immunol (2015) 0.87
Toll-like receptor 9 activation induces expression of membrane-bound B-cell activating factor (BAFF) on human B cells and leads to increased proliferation in response to both soluble and membrane-bound BAFF. Rheumatology (Oxford) (2013) 0.86
Effect of TACI signaling on humoral immunity and autoimmune diseases. J Immunol Res (2015) 0.84
The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity. J Immunol (2014) 0.82
IFN-β and multiple sclerosis: cross-talking of immune cells and integration of immunoregulatory networks. Cytokine Growth Factor Rev (2014) 0.82
Novel therapies for memory cells in autoimmune diseases. Clin Exp Immunol (2015) 0.79
IFN-β Therapy Regulates TLR7-Mediated Response in Plasmacytoid Dendritic Cells of Multiple Sclerosis Patients Influencing an Anti-Inflammatory Status. J Interferon Cytokine Res (2015) 0.78
IFN-β therapy modulates B-cell and monocyte crosstalk via TLR7 in multiple sclerosis patients. Eur J Immunol (2013) 0.78
Roles of ligands from the TNF superfamily in B cell development, function, and regulation. Semin Immunol (2014) 0.77